A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT ID: NCT02389985

Last Updated: 2020-05-28

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-07-31
• Study Completion Date: 2018-10-18

Brief Summary

The purpose of this study is to estimate the maximum tolerated doses (MTD) of CRLX101 when administered in combination with weekly paclitaxel in women with recurrent or persistent, epithelial ovarian, fallopian tube or primary peritoneal cancer.

Determine through pharmacokinetic evaluation(sometimes described as what the body does to a drug, refers to the movement of drug into, through and out of the body-the time and course of its absorption, bioavailability, distribution, metabolism, and excretion) whether or not the disposition of paclitaxel is affected by the concurrent administration of CRLX101.

Detailed Description

Recurrent ovarian cancer represents a therapeutic challenge. Patients with resistant disease, showing progression within six months of platinum-containing therapy, have a poor prognosis, with median overall survival (OS) approximately 12 months.Ultimately most patients with recurrent disease ultimately develop platinum resistance, and novel strategies are needed.

In this setting the most active agents are pegylated liposomal doxorubicin (PLD), paclitaxel and topotecan. Multiple trials have demonstrated that combination therapy produces increased toxicity without improved efficacy.

This study proposes to examine the combination of CRLX101 in combination with weekly paclitaxel. Preclinical studies show synergistic activity in the SKOV3 human ovarian cancer xenograft ovarian cancer cell lines (14), as well as in vivo (15,16), perhaps via an antiangiogenic mechanism.

Conditions

Ovarian Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

CRLX101 and weekly paclitaxel

CRLX101 and weekly paclitaxel administered by IV on days 1 and 15 of a 28 day cycle. Paclitaxel only is administered by IV on day 8.

Group Type: EXPERIMENTAL

CRLX101

Intervention Type: DRUG

Paclitaxel

Intervention Type: DRUG

Interventions

CRLX101

Intervention Type: DRUG

Paclitaxel

Intervention Type: DRUG

Other Intervention Names

NLG207; Taxol

Eligibility Criteria

Inclusion Criteria

1. Patients must have recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Histologic documentation of the original primary tumor is required via the pathology report.

2. Patient must have measurable disease or detectable (non-measurable) disease:

Measurable disease will be defined by RECIST 1.1.

3. Patients must have adequate bone marrow, renal, hepatic, and neurologic functions

4. Patients should be free of active infection requiring parenteral antibiotics.

5. Any other prior therapy directed at the malignant tumor, including chemotherapy, bevacizumab or other biologic or targeted agents and immunologic agents, must be discontinued at least 21 days (three weeks) prior to registration.

6. Any prior radiation therapy must be discontinued at least four weeks prior to registration.

7. Major surgery within 28 days (four weeks) prior to registration.

8. Patients must have had one prior platinum-based chemotherapeutic regimen for management of primary disease.

9. Patients must have a GOG performance status of 0 or 1.

10. Patients who will be enrolled under protocol amendment # 2 must have previously received bevacizumab, either discontinued due to intolerability, or progressed after at least 2 cycles of bevacizumab

Exclusion Criteria

1. Patients who have had previous treatment with:

• CRLX101 or with any topoisomerase I therapy;
• Weekly paclitaxel for recurrent or persistent disease.

2. Patients with a history of other invasive malignancies, with the exception of non-melanoma skin, are excluded if:

• There is any evidence of other malignancy being present within the last three years;
• Previous cancer treatment contraindicates this protocol therapy.

3. Patients with known active hepatitis or HIV.

4. Patients with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first dose of study drug.

5. Patients with clinically significant cardiovascular disease.

6. Patients with serous non-healing wound, ulcer, or bone fracture.

7. Patients with active bleeding or pathologic conditions that carry high risk of bleeding

8. Patients with clinical symptoms or signs of gastrointestinal obstruction and who require parenteral hydration and/or nutrition.

9. Patients with active infection requiring parenteral antibiotics.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

NewLink Genetics Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Massachusetts General Hospital

Boston, Massachusetts, United States

Washington University

St Louis, Missouri, United States

The Ohio State University

Columbus, Ohio, United States

University of Oklahoma / Stephenson Cancer Center

Oklahoma City, Oklahoma, United States

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Women & Infants Hospital of Rhode Island

Providence, Rhode Island, United States

University of Virginia Health System

Charlottesville, Virginia, United States

Countries

United States

References

Duska LR, Krasner CN, O'Malley DM, Hays JL, Modesitt SC, Mathews CA, Moore KN, Thaker PH, Miller A, Purdy C, Zamboni WC, Lucas AT, Supko JG, Schilder RJ. A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol. 2021 Mar;160(3):688-695. doi: 10.1016/j.ygyno.2020.12.025. Epub 2020 Dec 31.

Reference Type: DERIVED

PMID: 33390325 (View on PubMed)

Other Identifiers

CRLX101-209

Identifier Type: -

Identifier Source: org_study_id